Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

12.14

Margin Of Safety %

Put/Call OI Ratio

0.6

EPS Next Q Diff

-0.07

EPS Last/This Y

-0.95

EPS This/Next Y

-0.71

Price

20.39

Target Price

58.54

Analyst Recom

1.27

Performance Q

2.11

Relative Volume

1.49

Beta

1.13

Ticker: CLDX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02CLDX19.970.420.758080
2025-06-03CLDX19.850.430.008125
2025-06-04CLDX19.670.420.008147
2025-06-05CLDX19.510.420.178156
2025-06-06CLDX21.360.420.118176
2025-06-09CLDX20.70.420.738184
2025-06-10CLDX20.80.460.008957
2025-06-11CLDX20.410.570.077715
2025-06-12CLDX20.350.570.057744
2025-06-13CLDX21.240.560.837852
2025-06-16CLDX20.350.461.068256
2025-06-17CLDX20.040.470.008436
2025-06-18CLDX20.70.471.118441
2025-06-20CLDX20.520.470.038443
2025-06-23CLDX20.350.660.004210
2025-06-24CLDX21.640.640.044317
2025-06-25CLDX21.470.610.004446
2025-06-26CLDX21.180.610.034447
2025-06-27CLDX20.270.600.674487
2025-06-30CLDX20.360.600.034492
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02CLDX19.97-55.8-37.7-3.43
2025-06-03CLDX19.87-55.8-29.2-3.43
2025-06-04CLDX19.67-55.8-27.0-3.43
2025-06-05CLDX19.53-55.8-28.1-3.43
2025-06-06CLDX21.33-55.8-79.9-3.43
2025-06-09CLDX20.71-55.8-17.7-3.43
2025-06-10CLDX20.92-55.8-37.0-3.43
2025-06-11CLDX20.41-55.8-20.0-3.43
2025-06-12CLDX20.35-55.8-30.1-3.43
2025-06-13CLDX21.23-55.8-53.4-3.43
2025-06-16CLDX20.34-55.9-11.4-3.40
2025-06-17CLDX20.04-55.9-33.1-3.40
2025-06-18CLDX20.82-55.9-60.1-3.40
2025-06-20CLDX20.50-55.9-33.0-3.40
2025-06-23CLDX20.36-55.9-37.4-3.40
2025-06-24CLDX21.66-55.9-72.2-3.40
2025-06-25CLDX21.47-55.9-36.6-3.40
2025-06-26CLDX21.16-55.9-33.5-3.40
2025-06-27CLDX20.27-55.9-19.8-3.40
2025-06-30CLDX20.39-55.9-43.3-3.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02CLDX0.00-5.0714.15
2025-06-03CLDX0.00-5.0714.15
2025-06-04CLDX0.00-5.0714.15
2025-06-05CLDX0.00-5.0714.15
2025-06-06CLDX0.00-5.0714.15
2025-06-09CLDX0.00-5.0514.15
2025-06-10CLDX0.00-5.0514.15
2025-06-11CLDX0.00-5.0512.98
2025-06-12CLDX0.00-5.0512.98
2025-06-13CLDX0.00-5.0512.98
2025-06-16CLDX0.00-5.0512.98
2025-06-18CLDX0.00-5.0512.98
2025-06-20CLDX0.00-5.0512.98
2025-06-23CLDX0.00-5.0412.98
2025-06-24CLDX0.00-5.0412.98
2025-06-25CLDX0.00-5.0412.98
2025-06-26CLDX0.00-5.0412.14
2025-06-27CLDX0.00-5.0412.14
2025-06-30CLDX0.00-5.0412.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.81

Avg. EPS Est. Current Quarter

-0.84

Avg. EPS Est. Next Quarter

-0.88

Insider Transactions

Institutional Transactions

-5.04

Beta

1.13

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

24

Growth Score

36

Sentiment Score

3

Actual DrawDown %

64.4

Max Drawdown 5-Year %

-73.1

Target Price

58.54

P/E

Forward P/E

PEG

P/S

178.72

P/B

1.92

P/Free Cash Flow

EPS

-2.7

Average EPS Est. Cur. Y​

-3.4

EPS Next Y. (Est.)

-4.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2366.07

Relative Volume

1.49

Return on Equity vs Sector %

-49.3

Return on Equity vs Industry %

-30.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-43.3
Celldex Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 186
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today
news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance
stock history CLDX – Celldex Therapeutics, Inc. invest stock market
stock prices CLDX premarket after hours
ticker CLDX fair value insiders trading